Long COVID Clinical Trial
— EJerSA-COVIDOfficial title:
Effect of Different Types of Supervised Exercise Programs on Cardiorespiratory and Muscular Fitness, Pain, Fatigue, Mental Health and Inflammatory and Oxidative Stress Biomarkers in Older COVID-19 Survivors. (EJerSA-COVID-19)
Verified date | March 2024 |
Source | Campus docent Sant Joan de Déu-Universitat de Barcelona |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Many patients with COVID-19 present the so-called post-acute sequelae of COVID-19 such as fatigue, post-stress discomfort, dyspnea, headache, pain mental impairment, incapacity to perform daily physical tasks ant exercise intolerance. This study aims to investigate the effects of different exercise programs on physical and mental fitness, physical condition and biomarkers of the immune system and oxidative stress in older COVID-19 survivors. Methods: The sample will be made up of 120 eligible participants, over the age of 60 years who have had COVID-19 disease and are survivors and present persistent COVID-19 symptomatology diagnosed by the corresponding physician. The participants will be randomly assigned to the experimental groups: supervised endurance group (SEG, n = 30), supervised strength group (SSG, n = 30), supervised concurrent group (SCG, n = 30), which will perform the corresponding exercise program 3 days a week compared to the control group (CG, n = 30), which will not carry out a supervised exercise program. The design of this project will include assessment of cardiorespiratory fitness, muscle fitness, pain and mental health, and biomarkers of inflammation and oxidative stress.
Status | Completed |
Enrollment | 120 |
Est. completion date | January 31, 2024 |
Est. primary completion date | September 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Persons of both sexes (and different expression of gender) older than 60 years of age. - No history of physical diseases and no disease or disability that limits participation in the exercise program or precludes the corresponding measurement/evaluations. - Be able to communicate without difficulty. - Be able to understand the objectives of the project and provide informed consent. In this case, the consent form will be signed. - Not taking any medication that can affect normal performance of the exercise program and the evaluations Exclusion Criteria: - Having acute or terminal disease or any other disease that may affect the normal practice of a supervised exercise program and the corresponding evaluations. - Consumption of alcohol or drugs. - Be performing any type of activity that may interfere in carrying out the supervised exercise program or the evaluations. - Not completing the study once initiated or wishing to participate in the control group. |
Country | Name | City | State |
---|---|---|---|
Spain | Campus Docent Sant Joan de Déu. Universitat de Barcelona | Sant Boi De Llobregat | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Campus docent Sant Joan de Déu-Universitat de Barcelona | Hospital de Mataró, University of Barcelona |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiorespiratory fitness: absolute oxygen uptake | absolute oxygen uptake (peak VO2) in L/min | 1 week per group | |
Primary | Cardiorespiratory fitness: relative oxygen uptake | relative oxygen uptake (peak VO2) in mL/kg/min | 1 week per group | |
Primary | Cardiorespiratory fitness: ventilation | minute ventilation (VE) in L/min. | 1 week per group | |
Primary | Cardiorespiratory fitness: ventilatory equivalent for oxygen | Ventilatory equivalent for oxygen (VE/VO2) | 1 week per group | |
Primary | Cardiorespiratory fitness: ventilatory equivalent for carbon dioxide | Ventilatory equivalent for carbon dioxide (VE/VCO2) | 1 week per group | |
Primary | Cardiorespiratory fitness: respiratory exchange ratio | Respiratory exchange ratio (RER) | 1 week per group | |
Primary | Cardiorespiratory fitness: End-tidal partial pressure | End-tidal partial pressure of oxygen and carbon dioxide (PetO2 and PetCO2, respectively) in mmHg. | 1 week per group | |
Primary | Muscular fitness: Sit and stand test | Sit and stand test for 30 seconds. The number of times in 30 seconds the participant can completely stand up from a seated position with the back straight and the feet on the floor without pushing with the arms will be counted. | 1 week per group | |
Primary | Muscular fitness: countermovement jump | Countermovement jumps: Flight Height in cm | 1 week per group | |
Primary | Muscular fitness: countermovement test | Countermovement jumps: power output of the lower extremities in watts | 1 week per group | |
Primary | Muscular fitness: Upper limb strength | This will be evaluated with the bicep curl test made with a 2 kg weight for women and a 4 Kg weight for men. The number of elbow curls made in 30 seconds with each upper limb will be counted. | 1 week per group | |
Primary | Muscular fitness: hand grip strength | Hand grip strength: Force in Newtons Motor Agility/Dynamic balance: This will be evaluated with the 8-foot up and go test. The best of two attempts will be registered | 1 week per group | |
Primary | Muscular fitness: Motor Agility/Dynamic balance | Motor Agility/Dynamic balance: This will be evaluated with the 8-foot up and go test. The best of two attempts will be registered in seconds | 1 week per group | |
Primary | Muscular fitness: Isokinetic strength test | The isokinetic knee flexor and extensor test: peak torque in N m | 1 week per group | |
Primary | Muscular fitness: Isokinetic strength testing | The isokinetic knee flexor and extensor test: power output in Watts | 1 week per group | |
Primary | Body composition: fat mass | Fat mass will be assessed by bioelectrical impedance analysis in kg and percentage of body weight. | 1 week per group | |
Primary | Body composition: fat free mass | Fat free mass will be assessed by bioelectrical impedance analysis in kg and percentage of body weight. | 1 week per group | |
Primary | Body composition: muscle mass | Muscle mass will be assessed by bioelectrical impedance analysis in kg and percentage of body weight. | 1 week per group | |
Primary | Concentration of oxidative stress biomarkers: thiobarbituric acid reactive substances | Determination of oxidized lipids by the thiobarbituric acid reactive substances (TBARS) in mmols (fluorimetry technique). | 1 week per group | |
Primary | Concentration of oxidative stress biomarkers: Advanced Oxidation Protein Products | Determination of oxidized proteins by the Advanced Oxidation Protein Products (AOPP) in nmol Cl-T/mg protein, (colorimetry technique) | 1 week per group | |
Primary | Concentration of oxidative stress biomarkers: nitrites and nitrates | Determination of nitrites and nitrates (colorimetry) in nmol/mL | 1 week per group | |
Primary | Concentration of biomarkers of antioxidant enzymes: superoxide dismutase | superoxide dismutase (SOD) in units/mL | 1 week per group | |
Primary | Concentration of biomarkers of antioxidant enzymes: catalase | catalase (CAT) in units/mL | 1 week per group | |
Primary | Concentration of biomarkers of antioxidant enzymes: glutathion peroxidase | Glutathion peroxidase (GPx) in units/mL. | 1 week per group | |
Primary | Concentration of inflammation biomarkers: Interleukines | Interleukin 6 and 10 (IL-6 and IL-10) in ng/mL | 1 week per group | |
Primary | Concentration of inflammation biomarkers: adiponectin | adiponectin in mg/L | 1 week per group | |
Primary | Concentration of biomarkers of inflammation: Tumor necrosis factor | Tumor Necrosis Factor-alpha in pg/mL | 1 week per group | |
Primary | Evaluation of the degree of pain using the pupillometer: pupil diameter | basal and maximum diameter of the pupil in mm | 1 week per group | |
Primary | Evaluation of the degree of pain using the pupillometer:variation of pupil | percentage of variation of pupil diameter in % | 1 week per group | |
Primary | Evaluation of the degree of pain using the pupillometer: pupil variation | variation of the pupil in mm | 1 week per group | |
Primary | Evaluation of the degree of pain using the pupillometer: Intensity of reflex of dilatation | Intensity of reflex of dilatation, latency. | 1 week per group | |
Primary | Evaluation of the degree of pain with a pressure algometer: algometers | Pain will be quantified with a pressure algometer + pupillometer in older COVID-19 survivors.
A pressure algometer allows the application of a controlled and quantifiable nociceptive stimulus on a body surface. Algometers apply a pressure stimulus that can be useful for applying a standardized painful stimulus, having a different nature from that applied with the pupillometer which is a stimulus of electric origin. |
1 week per group | |
Primary | Mental health | Psychosocial variables will be evaluated using the Hospital Anxiety and Depression Scale (HADS), which is made up of 7 items for anxiety and depression. Each item of the anxiety subscale (HADS-A) and the depression subscale (HADS-D) will be scored on a scale of 4 points from 0 (none) to 3 (much more). The highest scores indicate the highest levels of anxiety or depression | 1 week per group |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05926505 -
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Completed |
NCT05552612 -
Health-related Quality of Life and Long COVID
|
||
Completed |
NCT05531019 -
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A
|
N/A | |
Not yet recruiting |
NCT04949386 -
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
|
Phase 2 | |
Recruiting |
NCT06118112 -
Living With Long COVID: LONGCOVID-EXPERIENCE
|
||
Completed |
NCT05185674 -
Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
|
||
Active, not recruiting |
NCT05965752 -
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
|
N/A | |
Active, not recruiting |
NCT05965739 -
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
|
N/A | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Recruiting |
NCT05606211 -
Pain in Long COVID-19: The Role of Sleep
|
||
Active, not recruiting |
NCT05713266 -
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
|
||
Completed |
NCT05601180 -
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
|
N/A | |
Completed |
NCT05679505 -
Vagus Nerve Stimulation for Post-COVID Syndrome
|
N/A | |
Not yet recruiting |
NCT06045338 -
Mind Body Intervention for Long COVID
|
N/A | |
Recruiting |
NCT06091358 -
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
|
N/A | |
Recruiting |
NCT05566392 -
Longterm Influence of Pediatric Long COVID Syndrome
|
||
Recruiting |
NCT05855369 -
Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss
|
Phase 2/Phase 3 | |
Recruiting |
NCT05572346 -
Digital App for Telerehabilitation in Respiratory Diseases
|
||
Recruiting |
NCT06316843 -
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
|
Phase 2 |